SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a 1.5 million dollar grant from the National Science Foundation, which investors see as a confirmation of the company's status as a leader in government-backed quantum initiatives. The community is actively debating the stock's long-term potential versus concerns over high valuations and the impact of broader market volatility on the quantum sector.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await the July 29th FDA Advisory Committee review of deramiocel, with the community closely monitoring for details on label breadth and potential FDA concerns ahead of the August 22nd decision date. Sentiment is heavily focused on the drug's clinical data from the HOPE-3 trial and a recent physician-led letter to the FDA advocating for a dual-indication approval covering both skeletal muscle function and cardiomyopathy.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following a record-breaking $266 million contract award from the U.S. Space Force for multiple suborbital missions. While the community is actively discussing this major government validation and expansion into a new launch complex in Alaska, many investors remain focused on the broader volatility of the space sector and are expressing frustration over the stock's sensitivity to macroeconomic headwinds and peer performance.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a combination of lower-than-anticipated monthly sales data and uncertainty surrounding potential competition from AstraZeneca's rival therapeutic. While some community members view the sell-off as a temporary market overreaction or short-selling pressure ahead of upcoming J-code reimbursement catalysts, others are expressing concern over recent executive departures and the need for stronger leadership to drive commercial momentum.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after argenx agreed to acquire the company in a significant all-cash deal, adding the FB102 antibody to its immunology pipeline. Investors are actively discussing the premium valuation provided by the acquisition and the potential future of the CD122-targeting platform within the broader immunology space.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward pressure and market volatility following a major leadership transition and ongoing concerns regarding competitive threats in the multiple myeloma space. While the community remains divided, many investors are focused on the long-term potential of its CARVYKTI sales and a robust pipeline, leading to active debates about whether the current price represents a strategic buying opportunity or a signal to brace for further instability.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is facing increased volatility as investors weigh its long-term potential in the trapped-ion quantum computing space against broader market rotation and short-term technical selling. While community sentiment remains polarized between long-term believers citing the company's backlog and strategic acquisition plans and bears focused on near-term valuation, active discussion is dominated by debates over entry levels and the impact of the pending SkyWater integration on the stock's future trajectory.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is currently trending as the market reacts to shifting geopolitical tensions between the U.S. and Iran, specifically community discussions surrounding the potential for ceasefire agreements and supply volatility. Investors are actively debating the impact of ongoing Middle East headlines on energy prices while monitoring the structural support levels and potential for leveraged decay in this oil-tracking instrument.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors respond to new executive orders designed to accelerate national quantum technology leadership and upgrade data security standards. The community is actively debating the stock's potential as a government-backed play, with many participants weighing the influence of federal catalysts against concerns regarding long-term cash burn and past volatility.

Anthropic

Anthropic is trending as it accelerates its IPO preparations amidst intense industry competition, while simultaneously navigating complex regulatory scrutiny regarding government AI access and export controls. The community remains deeply focused on the startup's massive infrastructure deals and strategic partnerships with cloud giants as it vies for dominance in the enterprise AI market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oatly Group (OTLY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Oatly Group (OTLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Transcript: Oatly Group Q2 2026 Earnings Conference Call

On Wednesday, Oatly Group (NASDAQ:OTLY) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This transcript is brought to you by Benzinga APIs. For real-timeread more...

Oatly Group (NASDAQ:OTLY) Announces Quarterly Earnings Results

Oatly Group (NASDAQ:OTLY - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.52. Oatly Group had a negative net margin of 17.71% and a negative return on equity of 236.71%. The...

Oatly Group Q1 Earnings Call Highlights

Oatly Group (NASDAQ:OTLY) reported what management called a "solid performance" in the first quarter of 2026, driven by revenue growth, gross margin expansion, and improved profitability, while reaffirming full-year guidance amid rising cost uncertainty tied to the conflict in the Middle East.

Firs...

Compared to Estimates, Oatly Group (OTLY) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Oatly Group (OTLY) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oatly Group (OTLY) Expected to Announce Quarterly Earnings on Wednesday

Oatly Group (NASDAQ:OTLY) will be releasing its Q1 2026 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...

Oatly Group AB Sponsored ADR (NASDAQ:OTLY) Receives Consensus Rating of "Hold" from Analysts

Shares of Oatly Group AB Sponsored ADR (NASDAQ:OTLY - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the stock, MarketBeat...

Oatly Group (NASDAQ:OTLY) Trading Down 0.5% - Time to Sell?

Oatly Group (NASDAQ:OTLY) Shares Down 0.5% - Here's What Happened...

Oatly Group AB Sponsored ADR (NASDAQ:OTLY) Receives Average Rating of "Hold" from Analysts

Oatly Group AB Sponsored ADR (NASDAQ:OTLY - Get Free Report) has been given a consensus recommendation of "Hold" by the seven analysts that are covering the company, Marketbeat reports. One research...

Oatly Group (NASDAQ:OTLY) Stock Price Down 1.7% - Should You Sell?

Oatly Group (NASDAQ:OTLY) Trading Down 1.7% - Here's Why...

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.79	--	--	N/A
Q2 '26	-$1.04	-$0.99	5.23%	BEAT
Q1 '26	-$0.95	-$0.38	60.21%	BEAT
Q4 '25	-$0.54	-$0.61	-12.44%	MISSED
Q3 '25	-$0.46	-$2.15	-365.37%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

OTLYOatly Group

Latest Earnings Results: Q2 '26

Historical Earnings

Latest OTLY News